Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II

被引:64
作者
Barinka, Cyril
Rovenska, Miroslava
Mlcochova, Petra
Hlouchova, Klara
Plechanovova, Anna
Majer, Pavel
Tsukamoto, Takashi
Slusher, Barbara S.
Konvalinka, Jan
Lubkowski, Jacek
机构
[1] NCI, Ctr Canc Res, Frederick, MD 21702 USA
[2] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Gilead Sci & IOCB Res Ctr, CR-10400 Prague, Czech Republic
[3] MGI Pharma Inc, Baltimore, MD 21224 USA
关键词
D O I
10.1021/jm070133w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to be neuroprotective in multiple preclinical models in which dysregulated glutamatergic transmission is implicated. Herein, we report crystal structures of the human GCPII complexed with three glutamate mimetics/derivatives, 2-(phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at 1.72, 1.62, and 2.10 angstrom resolution, respectively. Despite the structural differences between the distal parts of the inhibitors, all three compounds share similar binding modes in the pharmacophore (i.e., S1') pocket of GCPII, where they are stabilized by a combination of polar and van der Waals interactions. The structural diversity of the distal parts of the inhibitors leads to rearrangements of the S1' site that are necessary for efficient interactions between the enzyme and an inhibitor. The set of structures presented here, in conjunction with the available biochemical data, illustrates a flexibility of the GCPII pharmacophore pocket and highlights the structural features required for potent GCPII inhibition. These findings could facilitate the rational structure-based drug design of new GCPII inhibitors in the future.
引用
收藏
页码:3267 / 3273
页数:7
相关论文
共 45 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II [J].
Barinka, C ;
Rinnová, M ;
Sácha, P ;
Rojas, C ;
Majer, P ;
Slusher, BS ;
Konvalinka, J .
JOURNAL OF NEUROCHEMISTRY, 2002, 80 (03) :477-487
[3]   A high-resolution structure of ligand-free human glutamate carboxypeptidase II [J].
Barinka, Cyril ;
Starkova, Jana ;
Konvalinka, Jan ;
Lubkowski, Jacek .
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2007, 63 :150-153
[4]   THE ACTION OF NATURAL AND SYNTHETIC ISOMERS OF QUISQUALIC ACID AT A WELL-DEFINED GLUTAMATERGIC SYNAPSE [J].
BODEN, P ;
BYCROFT, BW ;
CHHABRA, SR ;
CHIPLIN, J ;
CROWLEY, PJ ;
GROUT, RJ ;
KING, TJ ;
MCDONALD, E ;
RAFFERTY, P ;
USHERWOOD, PNR .
BRAIN RESEARCH, 1986, 385 (02) :205-211
[5]   Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells [J].
Bruno, V ;
Wroblewska, B ;
Wroblewski, JT ;
Fiore, L ;
Nicoletti, F .
NEUROSCIENCE, 1998, 85 (03) :751-757
[6]   Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat [J].
Carpenter, KJ ;
Sen, S ;
Matthews, EA ;
Flatters, SL ;
Wozniak, KM ;
Slusher, BS ;
Dickenson, AH .
NEUROPEPTIDES, 2003, 37 (05) :298-306
[7]   Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase [J].
Davis, MI ;
Bennett, MJ ;
Thomas, LM ;
Bjorkman, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (17) :5981-5986
[8]  
DeLano W. L., 2002, PYMOL
[9]   Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors [J].
Ding, PY ;
Miller, MJ ;
Chen, Y ;
Helquist, P ;
Oliver, AJ ;
Wiest, O .
ORGANIC LETTERS, 2004, 6 (11) :1805-1808
[10]   The role of excitotoxicity in neurodegenerative disease: Implications for therapy [J].
Doble, A .
PHARMACOLOGY & THERAPEUTICS, 1999, 81 (03) :163-221